Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells

被引:0
作者
C.L. Pethiyagoda
D.R. Welch
T.P. Fleming
机构
[1] Washington University School of Medicine,Department of Surgery
[2] Pennsylvania State University School of Medicine,Jake Gittlen Cancer Research Institute
来源
Clinical & Experimental Metastasis | 2000年 / 18卷
关键词
CD26; dipeptidyl peptidase IV; invasion; Matrigel; metastasis;
D O I
暂无
中图分类号
学科分类号
摘要
Dipeptidyl peptidase IV (DPPIV) is a 110-kD, trans-membrane, ectoenzyme, with ubiquitous expression. DPPIV has numerous functions including involvement in T-cell activation, cell adhesion, digestion of proline containing peptides in the kidney and intestines, HIV infection and apoptosis, and regulation of tumorigenicity in certain melanoma cells. Constitutively expressed on numerous epithelial cell types, DPPIV is often disregulated in a variety of human malignancies. The most striking evidence of DPPIV down-regulation is found in transformed melanocytes, where nearly 100% of melanomas lack DPPIV expression. We have identified DPPIV as a gene that can alter the invasive potential of a number of melanoma cell lines. By transfecting the full-length cDNA of DPPIV, we have established stable melanoma cell lines that express comparable levels of the DPPIV protein as normal epidermal melanocytes. Matrigel invasion assays were utilized to study the effects of DPPIV expression on the invasive potential of these cells. The parental and vector transfectants readily migrated across the Matrigel while the invasiveness of DPPIV transfected cells was reduced by greater than 75%. The effects on cellular invasion are not attributed to overall growth characteristics, as both DPPIV expressing and non-expressing cells behave comparably in culture. We have also constructed mutants of DPPIV that lack either the extra-cellular serine protease activity or the six amino acid cytoplasmic domain. Both mutants were stably expressed in melanoma cells. Matrigel invasion assays performed with cells expressing the two mutant forms of the protein revealed phenotypic effects similar to wild type function. In this study, we have demonstrated that expression of a proteolytically active form of the DPPIV protein inhibits the invasiveness of malignant melanoma cell lines lacking endogenous DPPIV expression. Furthermore, we have shown that neither the protease activity nor the cytoplasmic domain of DPPIV is required for its anti-invasive activity.
引用
收藏
页码:391 / 400
页数:9
相关论文
共 50 条
  • [31] Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells
    Kim, Si Hyoung
    Kang, Jun Goo
    Kim, Chul Sik
    Ihm, Sung-Hee
    Choi, Moon Gi
    Yoo, Hyung Joon
    Lee, Seong Jin
    ENDOCRINE, 2018, 59 (02) : 383 - 394
  • [32] Potent and selective proline derived dipeptidyl peptidase IV inhibitors
    Edmondson, SD
    Mastracchio, A
    Beconi, M
    Colwell, LF
    Habulihaz, B
    He, HB
    Kumar, SJ
    Leiting, B
    Lyons, KA
    Mao, A
    Marsilio, F
    Patel, RA
    Wu, JK
    Zhu, L
    Thornberry, NA
    Weber, AE
    Parmee, ER
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (20) : 5151 - 5155
  • [33] Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumor human lung cells
    Dimitrova, Mashenka
    Ivanov, Ivaylo
    Todorova, Ralitza
    Stefanova, Nadezhda
    Moskova-Doumanova, Veselina
    Topouzova-Hristova, Tanya
    Saynova, Veselina
    Stephanova, Elena
    TISSUE & CELL, 2012, 44 (02) : 74 - 79
  • [34] The purification and characterisation of dipeptidyl peptidase IV from sheep lung
    Zeytunluoglu, A.
    Zihnioglu, F.
    AMINO ACIDS, 2015, 47 (08) : 1647 - 1648
  • [35] Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure
    Jackson, Edwin K.
    Dubinion, John H.
    Mi, Zaichuan
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2008, 35 (01): : 29 - 34
  • [36] Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
    Pala, L
    Ciani, S
    Bardini, G
    Pezzatini, A
    Sposato, I
    Cremasco, F
    Ognibene, A
    Rotella, C
    DIABETOLOGIA, 2005, 48 (06) : 1168 - 1172
  • [37] Eating disorders:: A role for dipeptidyl peptidase IV in nutritional control
    Hildebrandt, M
    Rose, M
    Mönnikes, H
    Reutter, W
    Keller, W
    Klapp, BF
    NUTRITION, 2001, 17 (06) : 451 - 454
  • [38] Inhibition of dipeptidyl peptidase IV by novel inhibitors with pyrazolidine scaffold
    Cheon, HG
    Kim, SS
    Kim, KR
    Rhee, SD
    Yang, SD
    Ahn, JH
    Park, SD
    Lee, JM
    Jung, WH
    Lee, HS
    Kim, HY
    BIOCHEMICAL PHARMACOLOGY, 2005, 70 (01) : 22 - 29
  • [39] New tetrazolium method for the histochemical localization of dipeptidyl peptidase IV
    Dikov, A
    Dimitrova, M
    Stoineva, I
    Halbhuber, KJ
    CELLULAR AND MOLECULAR BIOLOGY, 1999, 45 (02) : 225 - 231
  • [40] Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice
    Mentzel, S
    Dijkman, HBPM
    VanSon, JPHF
    Koene, RAP
    Assmann, KJM
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1996, 44 (05) : 445 - 461